Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario

Trastuzumab, a humanized monoclonal antibody, significantly improves outcomes in HER 2-neu positive breast cancer. The incidence of cardiotoxicity with trastuzumab is approximately 8 to 10%. This study was designed to analyze the incidence and risk factors associated with trastuzumab-related cardiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrivastva, Sarita, Bala, Stalin Chowdary, Chennamaneni, Rachana, Konatam, Meher Lakshmi, Pydi, Venkateswara Rao, Prasad, Kuruva Siva, Gundeti, Sadashivudu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691911/
https://www.ncbi.nlm.nih.gov/pubmed/38047057
http://dx.doi.org/10.1055/s-0043-1768039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691911/
https://www.ncbi.nlm.nih.gov/pubmed/38047057
http://dx.doi.org/10.1055/s-0043-1768039

Ejemplares similares